MYL6

Across TCGA pan-cancer cohorts, MYL6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYL6 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MYL6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYL6 expression acts as an unfavorable survival marker.

KIRC and BRCA are the cancer types where MYL6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.172	0.811	.002	16	view →
BRCA	DFS	Median	II,III,IV	0.418	0.889	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYL6–KIRC (OS)

Open the KIRC breakdown →